SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001493152-21-027447
Filing Date
2021-11-08
Accepted
2021-11-08 06:35:12
Documents
14
Period of Report
2021-11-08
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 36828
2 ex99-1.htm EX-99.1 184696
3 ex99-1_001.jpg GRAPHIC 3172
  Complete submission text file 0001493152-21-027447.txt   417708

Data Files

Seq Description Document Type Size
4 INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT mtnb-20211108.xsd EX-101.SCH 3049
5 INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT mtnb-20211108_lab.xml EX-101.LAB 34916
6 INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT mtnb-20211108_pre.xml EX-101.PRE 22805
7 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3760
Mailing Address 1545 ROUTE 206 SOUTH SUITE 302 BEDMINSTER NJ 07921
Business Address 1545 ROUTE 206 SOUTH SUITE 302 BEDMINSTER NJ 07921 908-484-8805
Matinas BioPharma Holdings, Inc. (Filer) CIK: 0001582554 (see all company filings)

IRS No.: 463011414 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38022 | Film No.: 211386445
SIC: 2834 Pharmaceutical Preparations